Ignite Creation Date:
2024-05-06 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 12:48 PM
Study NCT ID:
NCT03576937
Status:
COMPLETED
Last Update Posted:
2023-05-15
First Post:
2018-06-22
Brief Title:
Achieving Value in Cancer Diagnostics Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study
Sponsor:
University Health Network Toronto
Organization:
University Health Network Toronto
Study Overview
Official Title:
Achieving Value in Cancer Diagnostics Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study
Status:
COMPLETED
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VALUE
Brief Summary:
Current guidelines in non-small cell lung cancer recommend genomic assessment for mutations in EGFR and BRAF gene rearrangements in ALK and ROS1 and resistance mutations such as T790M upon progression during EGFR inhibitor therapy However obtaining sufficient tumour tissue to test for these molecular alterations as well as those with emerging targeted therapies is challenging in lung cancer A promising method to improve molecular diagnostic testing in lung and other cancers is the use of circulating cell-free DNA cfDNA obtained from blood samples or liquid biopsies This multi-centre prospective study will compare blood-based profiling using the GUARDANT360 assay to standard of care tissue-based profiling within the Canadian system
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None